CRISPR Gene Editing in Infectious Diseases Market is expected to reach USD 8.92 billion in 2034

CRISPR Gene Editing in Infectious Diseases Market Overview
The CRISPR Gene Editing in Infectious Diseases Market is witnessing rapid expansion, driven by growing applications of CRISPR-based tools in viral, bacterial, and fungal disease diagnostics and therapeutics. In 2024, the market was valued at USD 1.64 billion, reflecting strong adoption in academic research, genomic surveillance, and early-stage drug development programs.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/73646

By 2034, the market is expected to reach USD 8.92 billion, progressing at a remarkable 18.4% CAGR due to breakthroughs in CRISPR-based antiviral therapies, point-of-care diagnostics, and precision gene editing platforms. The post-pandemic era has highlighted the importance of tools that can provide rapid, accurate, and scalable solutions for pathogen detection and genome manipulation. CRISPR technologies such as Cas9, Cas12, Cas13, and prime editing are now being integrated across major infectious disease research pipelines.

Increasing investments from biotech companies, government funding for emerging pathogen surveillance, and the rise of synthetic biology-based therapeutics further underscore the market's strong growth potential.

Key Market Drivers
• Surge in infectious disease outbreaks and global genomic surveillance programs
• Expansion of CRISPR-based diagnostics such as CRISPR-Cas12/13 rapid detection kits
• Increased research in viral genome targeting, particularly for HIV, influenza, COVID-19, and HBV
• Growth in investment for gene therapy and synthetic biology
• Rising adoption in antimicrobial resistance (AMR) studies
• Accelerated regulatory pathways for innovative genetic tools
• Collaboration between biotech firms and academia for CRISPR therapeutic development

Market Restraints
• Safety concerns related to off-target gene editing
• Strict regulatory frameworks governing genetic modification
• High cost of CRISPR reagent kits and specialized laboratory equipment
• Ethical concerns related to human germline editing
• Limited availability of skilled researchers and infrastructure in emerging regions

Market Segmentation
By Product Type
• CRISPR Gene Editing Kits
• CRISPR Enzymes (Cas9, Cas12, Cas13)
• Guide RNA (gRNA) Products
• CRISPR Plasmids & Vectors
• CRISPR-Based Diagnostic Assay Kits
• Delivery Systems (Lipid Nanoparticles, Viral Vectors, Electroporation)

By Application
• Viral Diseases (HIV, COVID-19, Influenza, HBV, HCV)
• Bacterial Diseases (Tuberculosis, MRSA, AMR studies)
• Parasitic Diseases (Malaria, Leishmaniasis)
• Fungal Infections
• Genomic Surveillance & Epidemiology
• Drug Discovery & Development

By End User
• Academic & Research Institutes
• Biotechnology & Pharmaceutical Companies
• Diagnostic Laboratories
• Hospitals & Clinical Centers
• Government & Public Health Agencies

By Technology
• CRISPR-Cas9
• CRISPR-Cas12 (DETECTR)
• CRISPR-Cas13 (SHERLOCK)
• Base Editing
• Prime Editing
• CRISPR Interference (CRISPRi) & CRISPR Activation (CRISPRa)

Explore Full Report here: https://exactitudeconsultancy.com/reports/73646/crispr-gene-editing-in-infectious-diseases-market

Regional Analysis
North America
• Market share (2024): ~42%
• Largest hub for CRISPR research, high adoption in biotech, NIH-backed funding, and early regulatory acceptance.
• Strong ecosystem of CRISPR startups and genomic surveillance programs.

Europe
• Market share (2024): ~28%
• Growth driven by EU-sponsored infectious disease research programs and investments in AMR genomic studies.
• Significant progress in CRISPR diagnostics and public health initiatives.

Asia Pacific
• Fastest-growing region (CAGR: ~22% through 2034)
• Expanding biotech R&D in China, Japan, South Korea, Singapore, and India.
• Rising infectious disease burden and increased government funding for genomic innovation.

Latin America & Middle East/Africa
• Emerging markets adopting CRISPR-based diagnostics for regional outbreaks.
• Improvement in laboratory infrastructure accelerating uptake.

Competitive Landscape (20 Key Players)
1. CRISPR Therapeutics
2. Editas Medicine
3. Intellia Therapeutics
4. Mammoth Biosciences
5. Sherlock Biosciences
6. Caribou Biosciences
7. Beam Therapeutics
8. Synthego Corporation
9. Horizon Discovery
10. AstraZeneca
11. GeneCopoeia
12. Takara Bio Inc.
13. Thermo Fisher Scientific
14. New England Biolabs (NEB)
15. QIAGEN
16. Merck KGaA (Sigma-Aldrich)
17. Genscript Biotech Corporation
18. Agilent Technologies
19. Danaher Corporation
20. Becton Dickinson & Company
These companies are focusing on CRISPR therapeutic pipelines, diagnostic kits, research reagents, cloud-enabled bioinformatics, and delivery technology innovations.

Recent Developments
• 2024: Mammoth Biosciences introduced a next-generation CRISPR-based multi-pathogen detection platform.
• 2024: Intellia and Regeneron expanded their collaboration to target viral diseases using in vivo CRISPR therapies.
• 2023-2024: Sherlock Biosciences launched upgraded SHERLOCK CRISPR diagnostic kits for respiratory infections.
• 2024: CRISPR Therapeutics entered preclinical trials for CRISPR-based antiviral platforms targeting influenza and HIV.
• 2024: Several companies began applying CRISPR tools for AMR gene mapping in bacteria.
• EU: Increased Horizon Europe funding for CRISPR-enabled epidemiological surveillance of emerging pathogens.

Opportunities
• Development of CRISPR-based cures for chronic viral infections (HIV, HBV, HPV).
• Rapid, decentralized point-of-care testing for pandemic preparedness.
• Synthetic biology-driven programmable antimicrobials.
• High-precision gene editing systems (prime editing) for infectious diseases.
• AI-driven design of gRNA for pathogen genome mapping.
• Expansion in emerging markets through low-cost CRISPR diagnostic kits.

Conclusion
The CRISPR Gene Editing in Infectious Diseases Market is entering a breakthrough phase, propelled by strong demand for rapid diagnostics, genome-targeted therapeutics, and precision surveillance technologies. With a projected market value of USD 8.92 billion by 2034 and an impressive 18.4% CAGR, CRISPR-based solutions are set to play a pivotal role in the next decade of infectious disease control and clinical innovation.

North America remains the global leader, while Asia Pacific is emerging as the fastest-growing market. Increasing collaborations, strategic investments, and regulatory support will continue to open new avenues for CRISPR-enabled breakthroughs across the infectious diseases ecosystem.

This report is also available in the following languages : Japanese (感染症におけるCRISPR遺伝子編集:市場), Korean (감염성 질환에서의 CRISPR 유전자 편집: 시장), Chinese (CRISPR基因编辑在传染病领域的应用:市场), French (Édition génique CRISPR dans les maladies infectieuses : marché), German (CRISPR-Geneditierung bei Infektionskrankheiten: Markt), and Italian (Editing genetico CRISPR nelle malattie infettive: mercato), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/73646

Our More Reports:

PERK Inhibitors Market
https://exactitudeconsultancy.com/reports/72667/perk-inhibitors-market

CRISPR Gene Editing Therapies Market
https://exactitudeconsultancy.com/reports/72861/crispr-gene-editing-therapies-market

DNA Encoded Library Market
https://exactitudeconsultancy.com/reports/73115/dna-encoded-library-market

Metabolic and Cardiology Stem Cells Market
https://exactitudeconsultancy.com/reports/73138/metabolic-and-cardiology-stem-cells-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.